PKI - New PerkinElmer SARS-CoV-2 test kit for variants launched for research use

PerkinElmer (NYSE:PKI) has launched its NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 for research use which makes it faster and easier to detect virus variants. With positive SARS-CoV-2 samples, the kit detects mutations associated with all SARS-CoV-2 variants, including Omicron. PerkinElmer says that NEXTFLEX v2 reduces turnaround time by an average of three hours. The kit is intended for use by large laboratories. PerkinElmer has previously said its COVID-19 PCR tests are not impacted by the Omnicom variant.

For further details see:

New PerkinElmer SARS-CoV-2 test kit for variants launched for research use